A personalized approach to prescribing.
Pharmacogenetics is the study of how genetic variations affect individual’s response to medications. Pharmacogenetic testing provides predictive information about a patient’s ability to metabolize certain medications and what affect that medication has on a patient, enabling optimal medication choice and dosing. This can provide a unique and personalized treatment strategy, shorten the time needed to find an effective medication, and reduce risk for adverse drug reactions. The Informed PGx test enables clinicians to:
Identify effective therapies faster.
Achieve symptomatic relief without a lengthy trial-and error process.
Reduce negative effects.
Informed prescribing reduces risk for adverse drug reactions.
Understand genetic suitability.
Clear and actionable results provide personalized treatment options.
How does the Informed PGx test work?
Many patients have a gene variant that affects the function of one or more drug metabolizing enzymes—the cytochrome P450 enzymes. There are more than 50 cytochrome P450 enzymes, but just a handful of those enzymes control the metabolism of approximately 80% of prescription medications available today.1
All enzymes, including enzymes in the cytochrome P450 family, are produced by specific genes. Gene variants can lead to a change in the amount of enzyme produced in the liver, which leads to variations in the individual’s ability to metabolize medications. These variations in metabolism may contribute to toxicity in one patient and reduced effectiveness in another.2
The effectiveness of medication can also be altered by variants in pharmacodynamic genes. Informed PGx analyzes variants in both the pharmacokinetic and pharmacodynamic pathways.
This information is then used to organize the tested medications into one of three categories:
Informed PGx – Genetic Variants and Medications
The Informed PGx – Depression test includes analysis of genetic variants for CYP2D6, CYP2C9, CYP2C19, CYP2B6, CYP1A2, SLC6A4 and MTHFR that may affect metabolism of the following antidepressant medications:
The Informed PGx – Psychotropic test includes analysis of genetic variants for CYP2D6, CYP2C9, CYP2C19, CYP2B6, CYP1A2, SLC6A4 and MTHFR that may affect metabolism of the following antidepressant and psychotropic medications:
The Informed PGx – ADHD test includes analysis of genetic variants for CYP2D6, CES1, COMT and ADRA2A that may affect metabolism of the following ADHD medications: